MEDIPOST, signs a contract with SK Bioland for an ankle joint indication2019/01/02STEM CELL THERAPEUTIC
MEDIPOST acquires US Patent for the ‘Mesenchymal Stem Cell Culture Method’2018/10/24STEM CELL THERAPEUTIC
MEDIPOST acquires the Japanese patent in hair loss prevention and hair growth promoting composition2018/07/04STEM CELL THERAPEUTIC
MEDIPOST acquires patents on the “Mesenchymal Stem Cell Culture Method” in 6 European countries2018/06/27STEM CELL THERAPEUTIC
Significant increase in the revenue of MEDIPOST stem cell therapeutics CARTISTEM in comparison to the previous year2018/04/20STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent for Stem Cell Culture Medium Technique for Hair Loss Treatment2018/02/28STEM CELL THERAPEUTIC
MEDIPOST’s Alzheimer’s Disease Drug Approved by FDA for Clinical Trials2018/02/05STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent for its ‘CARTISTEM’ Production Technology’ in Six European Countries2017/12/06STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent for Core Alzheimer’s Disease Treatment Technology in Six European Countries2017/10/25STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent for Commercializing High-efficiency Technology to Culture Stem Cell2017/09/13STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in Canada for its Stem Cell-based Alzheimer’s Disease Treatment Composition2017/06/28STEM CELL THERAPEUTIC
MEDIPOST Submits Application for Product Authorization Amendment to Add Ankle Indications for CARTISTEM®2023/12/27
MEDIPOST Selected for a Government-Supported R&D Project Worth KRW 13 billion, to be Used for Global Market Expansion Including the U.S.2023/10/04
MEDIPOST’s CARTISEM®, Umbilical Cord Blood-derived Stem Cell Transplant Surgery Clinical Study Results Published in SCI-Level Journal2023/05/02
MEDIPOST Treats First Subject with CARTISTEM® in Japan Phase 3 Clinical Trial, Accelerating Clinical Development efforts in Japan2023/01/16
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022/12/01